Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (271)	$ (132)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sale of in-process research and development	(139)	(445)
Stock-based compensation expense	17	20
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	162	162
Accounts payable, accrued expenses and other	(126)	2
Other assets	1	39
Net cash used in operating activities	(356)	(354)
Cash flows from investing activities
Net proceeds from sale of in process research and development	139	445
Net cash provided by investing activities	139	445
Cash flows from financing activities
Proceeds from exercise of stock options	179
Net cash provided by financing activities	179
Net (decrease) increase in cash and cash equivalents	(38)	91
Cash and cash equivalents, beginning of period	19,439	14,203
Cash and cash equivalents, end of period	$ 19,401	$ 14,294